Abstract
Introduction Yellow Card Vaccine Monitor (YCVM) was established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to facilitate active monitoring of adverse reactions following COVID-19 vaccination and further characterise safety in populations under-represented in clinical trials.
Methods Randomly selected individuals were invited to register and actively contacted to seek further information on the vaccines received and adverse events they experienced. Demographics of patients recruited, and summaries of reported data, are presented alongside detailed analyses of the sub-cohort of pregnant and breast-feeding patients and analyses conducted to support regulatory assessment of two safety signals, menstrual disorders, and tinnitus.
Results 36,604 individuals registered, with 30,281 reporting vaccination. Median [IQR] follow-up was 184 days [14-367]. Demographics of the recruited cohort reflected the vaccinated population and timing of invitations. 15,764 (52.1%) of those reporting vaccination, reported experiencing at least one adverse reaction. However, nearly all were expected acute reactions and only 4,134 (13.7%) reported an event considered medically serious. The data raised no safety concerns in pregnant and breast-feeding patients. Reporting of menstrual disorders appeared stimulated by media interest, as seen in spontaneous reporting systems. Data on the incidence of tinnitus were used to support regulatory action on this signal.
Discussion Active surveillance provided a complimentary data source for monitoring the safety of COVID- 19 vaccines. However, further efforts are needed to recruit ethnic minorities. The technology developed has enhanced regulatory vigilance options and could be valuable in the future for actively monitoring the safety of innovative products used in small populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics committee of UK Health Research Authority (HRA) waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Agency provides information to the public in line with requirements of the Freedom of Information Act. In addition, organisations and individuals can apply for Yellow Card data for research purposes. Applications include provision of a protocol and will be considered by the UK Commission of Human Medicine's (CHM) Pharmacovigilance Expert Advisory Group.
